CLINICAL & PIPELINE·Drug Approval
FDA Approves Labeling Supplements for Fonseca Biosciences' XTORO (FINAFLOXACIN)
Fonseca Biosciences has secured FDA approval for two labeling supplements (SUPPL 4 and SUPPL 6) for its New Molecular Entity, XTORO (FINAFLOXACIN 0.3% otic suspension), on March 18, 2026. This regulatory update for the quinolone antimicrobial, originally approved in 2014, impacts commercial strategy, regulatory compliance, and supply chain management for stakeholders in the global chemical and life sciences industry.
90-Day Activity